Novo Nordisk has received European approval to acquire Catalent, a U.S. drug manufacturer responsible for producing a large portion of Novo Nordisk’s popular obesity drug, Wegovy. However ...

2024 was quite a year for significant strategic action among the pharmaceutical giants. Here are five key trends that will ...

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

We are constructive on markets and believe the recent correction offers a good entry point to start accumulation for long ...

Novo Nordisk should deliver a 24% CAGR over two years, driven by robust obesity drug market growth and improved operational performance, with an intrinsic value implying a 29% safety margin.

Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform.Don't Miss Our New Year's Offers:Discover the latest stocks ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.